<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576576</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000701</org_study_id>
    <secondary_id>GA2580TT</secondary_id>
    <secondary_id>Emory #07052168</secondary_id>
    <nct_id>NCT00576576</nct_id>
  </id_info>
  <brief_title>Evaluation of Atorvastatin on Atherosclerosis Composition</brief_title>
  <official_title>The Evaluation of Atorvastatin on Wall Shear Stress, Atherosclerosis Composition, and Microvascular Function in Patients With Moderate Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Atorvastatin on the coronary
      atherosclerosis plaque morphology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this project is to evaluate the effect of the cholesterol lowering drug
      Atorvastatin on the composition and character of coronary atherosclerosis (heart blockages).
      Atorvastatin is known to reduce cholesterol, reduce cardiac events, and halt the progression
      of coronary atherosclerosis. However, the reduction in cardiac events is out of proportion to
      the reductions in the total amount of atherosclerosis. Thus, the drug likely decreases
      cardiac events by changing the composition of the coronary atherosclerotic plaques. It is
      likely that the drug causes the &quot;heart blockage&quot; to change from a &quot;vulnerable plaque&quot; to a
      &quot;stable&quot; plaque. There are several features of &quot;vulnerable plaques&quot; that can be detected in
      arteries of the heart using intravascular ultrasound. The goal of this project is to examine
      the effects of atorvastatin on atherosclerosis plaque composition using this intravascular
      ultrasound in patients undergoing serial cardiac catheterizations. Our hypothesis is that
      atorvastatin will reduce the number of &quot;vulnerable plaques&quot; and increase the number of
      &quot;stable plaques&quot; seen by intravascular ultrasound. We plan to enroll a total of 20 patients.
      The patients will be evaluated by cardiac catheterization with intravascular ultrasound
      analysis and then be treated with atorvastatin for 6 months. These 20 patients will return to
      the cardiac catheterization laboratory 6 months later for a repeat catheterization with
      intravascular ultrasound evaluation.

      The secondary goal of this proposal is to evaluate in humans the relationship between
      coronary atherosclerosis (plaque buildup in the arteries of the heart) and wall shear stress
      (the force generated against the wall of the artery by the flow of blood). The reason for
      this sub-study is that there is great interest in understanding the characteristics that
      cause the progression of coronary atherosclerosis. Local forces such as shear stress may play
      an important role in the focal progression of &quot;vulnerable&quot; atherosclerotic plaques. Indeed,
      low shear stress is known to be an important factor in the early formation of
      atherosclerosis. However, the relationship of low shear stress to development and progression
      of advanced &quot;rupture prone&quot; (&quot;vulnerable&quot;) plaques has not been elucidated. Our hypotheses
      are: (1) &quot;Vulnerable plaques&quot; are more commonly located at areas of low shear stress(2)
      &quot;Vulnerable plaques&quot; at areas of low shear stress are more likely to progress over the
      following 6 months than plaques located in normal shear stress regions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Necrotic Core Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Virtual Histology-Intravascular Ultrasound (VH-IVUS) defined necrotic core cross sectional area (CSA) measured in each VH-IVUS frame and averaged over length of studied vessel at baseline and follow -up. Change in necrotic core CSA between baseline and follow-up was calculated (subtracting the baseline value from the follow-up value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Atheroma Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Change in atheroma volume between baseline and follow-up is reported. This was derived by subtracting the baseline value from the 6-month value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrous Plaque Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Change in fibrous plaque volume between baseline and follow-up. This was derived by subtracting the baseline value from the 6-month value.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this arm are given atorvastatin therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 80 mg a day</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients are eligible if they are undergoing catheterization for stable angina or
             acute coronary syndromes

          2. At the time of catheterization the patient has a &quot;moderate coronary&quot; lesion in the
             proximal 60mm of an epicardial coronary artery

          3. &quot;Moderate lesion&quot; is defined as a lesion deemed significant enough to warrant further
             evaluation using coronary flow reserve (CFR) and fractional flow reserve (FFR) by the
             treating physician

          4. Patient must have decision making capacity and consented prior to the catheterization

          5. Ages: All ages

          6. Performance Status: all levels

        Exclusion Criteria:

        1. Screening Exclusion Criteria:

          1. Patients with coronary bypass grafts

          2. Severe valvular heart disease

          3. Patients presenting with a ST segment elevation myocardial infarction (STEMI)

          4. Inability to provide informed consent prior to randomization

          5. Creatinine &gt;1.5

          6. Patients who are on a statin with an LDL &lt; 130.

          7. Any patient on a maximum dose of statin (atorvastatin 80mg, simvastatin 80mg,
             rosuvastatin 20mg, pravastatin 80mg, or fluvastatin 80mg)

          8. Uncontrolled diabetes requiring intensification of therapy

          9. Uncontrolled hypertension requiring the addition of angiotensin-converting enzyme
             inhibitor or angiotensin receptor blocker

        2. Angiographic Ineligibility Criteria:

          1. A Left Main lesion greater than 50% stenosis

          2. The moderate lesion is located beyond 60mm

          3. Collaterals

          4. Coronary Anatomy requiring coronary artery bypass grafting (CABG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Habib Samady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, Tsuchiya K, Minatoguchi S, Zhou X, Fujita H, Fujiwara H. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005 Jun 21;45(12):1946-53.</citation>
    <PMID>15963391</PMID>
  </reference>
  <results_reference>
    <citation>Samady H, Eshtehardi P, McDaniel MC, Suo J, Dhawan SS, Maynard C, Timmins LH, Quyyumi AA, Giddens DP. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease. Circulation. 2011 Aug 16;124(7):779-88. doi: 10.1161/CIRCULATIONAHA.111.021824. Epub 2011 Jul 25.</citation>
    <PMID>21788584</PMID>
  </results_reference>
  <results_reference>
    <citation>Eshtehardi P, McDaniel MC, Suo J, Dhawan SS, Avati Nanjundappa RP, Sawaya FJ, King AR, Oshinski JN, Taylor WR, Quyyumi AA, Giddens DP, Samady H. Coronary Plaque Progression Occurs Distal to Stenoses in Segments with Low Wall Shear Stress: A Prospective Evaluation in Patients with Coronary Artery Disease. Arterioscler Thromb Vasc Biol 2010;30(11);e251.</citation>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <results_first_submitted>November 28, 2012</results_first_submitted>
  <results_first_submitted_qc>August 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2013</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Habib Samady</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis, vulnerable plaque, IVUS, shear stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>27 subjects enrolled and followed up for 6 months All subjects were recruited between 2007 and 2009 at Emory University Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>All patients in this arm are given atorvastatin therapy.
Atorvastatin : Atorvastatin 80 mg a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>All patients in this arm are given atorvastatin therapy.
Atorvastatin : Atorvastatin 80 mg a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="46-68" lower_limit="46" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Necrotic Core Volume</title>
        <description>Virtual Histology-Intravascular Ultrasound (VH-IVUS) defined necrotic core cross sectional area (CSA) measured in each VH-IVUS frame and averaged over length of studied vessel at baseline and follow -up. Change in necrotic core CSA between baseline and follow-up was calculated (subtracting the baseline value from the follow-up value).</description>
        <time_frame>6 months</time_frame>
        <population>All enrolled patients with complete data set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>All patients in this arm are given atorvastatin therapy.
Atorvastatin : Atorvastatin 80 mg a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Necrotic Core Volume</title>
          <description>Virtual Histology-Intravascular Ultrasound (VH-IVUS) defined necrotic core cross sectional area (CSA) measured in each VH-IVUS frame and averaged over length of studied vessel at baseline and follow -up. Change in necrotic core CSA between baseline and follow-up was calculated (subtracting the baseline value from the follow-up value).</description>
          <population>All enrolled patients with complete data set</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Atheroma Volume</title>
        <description>Change in atheroma volume between baseline and follow-up is reported. This was derived by subtracting the baseline value from the 6-month value.</description>
        <time_frame>6 months</time_frame>
        <population>All enrolled patients with complete data set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>All patients in this arm are given atorvastatin therapy.
Atorvastatin : Atorvastatin 80 mg a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atheroma Volume</title>
          <description>Change in atheroma volume between baseline and follow-up is reported. This was derived by subtracting the baseline value from the 6-month value.</description>
          <population>All enrolled patients with complete data set</population>
          <units>mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-20.4" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fibrous Plaque Volume</title>
        <description>Change in fibrous plaque volume between baseline and follow-up. This was derived by subtracting the baseline value from the 6-month value.</description>
        <time_frame>6 months</time_frame>
        <population>All enrolled patients with complete data set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>All patients in this arm are given atorvastatin therapy.
Atorvastatin : Atorvastatin 80 mg a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fibrous Plaque Volume</title>
          <description>Change in fibrous plaque volume between baseline and follow-up. This was derived by subtracting the baseline value from the 6-month value.</description>
          <population>All enrolled patients with complete data set</population>
          <units>mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-15.2" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>All patients in this arm are given atorvastatin therapy.
Atorvastatin : Atorvastatin 80 mg a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No adverse events to report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Habib Samady</name_or_title>
      <organization>Emory</organization>
      <phone>4047781237</phone>
      <email>hsamady@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

